Traders should monitor the upcoming Phase 2b trial initiation and long-term toxicology study completion as key catalysts. Positive Phase 2 data could drive significant upside given the lack of oral targeted therapies in mast cell-driven diseases.
Price Chart
Executive Summary
Septerna announced positive Phase 1 results for SEP-631, an oral MRGPRX2 negative allosteric modulator, showing robust, dose-dependent inhibition of mast cell activation with a favorable safety profile and pharmacokinetics supporting once-daily dosing. The company plans to advance SEP-631 into a Phase 2b trial for chronic spontaneous urticaria (CSU) in the second half of 2026 and explore additional mast cell-driven indications.
Key Facts
- SEP-631 demonstrated complete inhibition of icatibant-induced skin wheal formation at doses as low as 10 mg once daily.
- The drug was well-tolerated with an adverse event profile comparable to placebo and no serious adverse events.
- Pharmacokinetic data show a half-life of ~24 hours, supporting once-daily oral dosing without food restrictions.
- Phase 2b trial in chronic spontaneous urticaria (CSU) planned for second half of 2026, pending toxicology study completion.
- Additional development planned for chronic inducible urticaria and evaluation in atopic dermatitis, interstitial cystitis, migraine, and asthma.
Financial Impact
No direct financial impact reported; clinical milestone de-risks development and supports valuation upside.
Risk Factors
- Phase 1 results in healthy volunteers may not translate to efficacy in CSU patients.
- Regulatory delays or safety signals in long-term toxicology studies could postpone Phase 2 initiation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3246935 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 21d ago | Press Release | $38.51 $38.69 | ▲ +0.47% | ▲ +0.69% | $38.27 (−0.62%) |
Sep 3, 2026 28d ago | 3 | $36.75 $39.55 | ▲ +7.62% | ▲ +8.83% | $38.27 (+4.14%) |
Aug 25, 2026 5w ago | 8-K | $41.30 $37.68 | ▼ −8.77% | ▼ −8.23% | $38.27 (−7.34%) |
Aug 14, 2026 6w ago | Insider Cluster | $44.20 $40.52 | ▲ +8.33% | ▲ +7.14% | $38.27 (+13.42%) |
Aug 14, 2026 6w ago | Insider Cluster | $44.20 $40.52 | ▲ +8.33% | ▲ +7.14% | $38.27 (+13.42%) |
Aug 12, 2026 7w ago | 144 | $45.14 $40.79 | ▲ +9.64% | ▲ +7.67% | $38.27 (+15.22%) |
Aug 12, 2026 7w ago | 144 | $45.14 $40.79 | ▲ +9.64% | ▲ +7.67% | $38.27 (+15.22%) |
Aug 10, 2026 7w ago | 8-K | $47.76 $43.80 | ▼ −8.29% | ▼ −7.89% | $38.27 (−19.87%) |
Aug 10, 2026 7w ago | Press Release | $47.76 $43.80 | ▼ −8.29% | ▼ −7.89% | $38.27 (−19.87%) |
Jul 2, 2026 13w ago | Insider Cluster | $34.00 $37.84 | ▲ +11.29% | ▲ +10.36% | $38.27 (+12.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access